Combination of human tumor necrosis factor-alpha (hTNF-alpha) gene delivery with gemcitabine is effective in models of pancreatic cancer (Q39851146)

15 September 2017

Combination of human tumor necrosis factor-alpha (hTNF-alpha) gene delivery with gemcitabine is effective in models of pancreatic cancer (English)

1 reference

15 September 2017

0 references

1 reference

S R Murugesan

1

1 reference

15 September 2017

C R King

2

1 reference

15 September 2017

R Osborn

3

1 reference

15 September 2017

W R Fairweather

4

1 reference

15 September 2017

E M O'Reilly

5

1 reference

15 September 2017

M O Thornton

6

1 reference

15 September 2017

L L Wei

7

1 reference

15 September 2017

15 May 2009

1 reference

15 September 2017

1 reference

15 September 2017

16

1 reference

15 September 2017

11

1 reference

15 September 2017

841-847

1 reference

https://scigraph.springernature.com/pub.10.1038/cgt.2009.32

15 September 2017

0 references

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.32

Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.32

Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.32

Tumor necrosis factor, cancer and anticancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.32

Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.32

Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.32

TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.32

TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.32

Possible antitumor activity of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.32

Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.32

Combined gene therapy and ionizing radiation is a novel approach to treat human esophageal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.32

Spatial and temporal control of gene therapy using ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.32

Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.32

Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.32

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.32

7 January 2021

Insights into differential endostatin activity

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.32

7 January 2021

Transcriptional control of viral gene therapy by cisplatin

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.32

7 January 2021

Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.32

7 January 2021

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.32

7 January 2021

Endothelial cell dysfunction, injury and death.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.32

7 January 2021

Identifiers

DOI

10.1038/CGT.2009.32

1 reference

15 September 2017

1 reference